Carvedilol
Carvedilol is a pharmaceutical drug with 130 clinical trials. Currently 18 active trials ongoing. Historical success rate of 88.9%.
Success Metrics
Based on 56 completed trials
Phase Distribution
Phase Distribution
16
Early Stage
18
Mid Stage
66
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
77.8%
56 of 72 finished
22.2%
16 ended early
18
trials recruiting
130
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
Carvedilol in HF With Preserved EF
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Clinical Trials (130)
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
Carvedilol in HF With Preserved EF
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial.
Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis.
KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)
Cardiac Changes in Early Parkinson's Disease: A Follow up Study
Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis.
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 130